Complement-mediated hemolytic uremic syndrome associated with postpartum hemorrhage: case series and systematic review of individual participant data

Autor: Anna Gurevich-Shapiro, Sharon Orbach-Zinger, Avi Leader, Galia Stemer, Arnon Wiznitzer, Pierre Singer, Miriam Davidovits, Michael Shapiro, Eva N. Hamulyák, Pia Raanani, Galia Spectre

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 8, Pp 102579- (2024)

Background: Postpartum hemorrhage is considered a risk factor for pregnancy-associated complement-mediated hemolytic uremic syndrome (CM-HUS; previously known as atypical hemolytic uremic syndrome) but has not been systematically studied. Objectives:

Externí odkaz: https://doaj.org/article/6dfd371bbacb480d9edb000862f93a6e

Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis A multicentre retrospective cohort study

Autor: Eva N. Hamulyák, Luuk J. J. Scheres, Jack R van Duuren, Saskia Middeldorp, Johannes J. Duvekot, Stefanie E Damhuis, Sanne J. Gordijn, Sarwa Darwish Murad, Mandy N Lauw, Jenneke Leentjens, Barbara A. Hutten, Hanke M. G. Wiegers, Wessel Ganzevoort

Publikováno v: BJOG : an International Journal of Obstetrics and Gynaecology, 129, 608-617
BJOG: An International Journal of Obstetrics and Gynaecology, 129(4), 608-617. Wiley-Blackwell Publishing Ltd
BJOG : An International Journal of Obstetrics and Gynaecology, 129(4), 608-617. Wiley
BJOG: An International Journal of Obstetrics and Gynaecology. Wiley-Blackwell
BJOG : an International Journal of Obstetrics and Gynaecology, 129, 4, pp. 608-617

Contains fulltext : 248726.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To evaluate current practice and outcomes of pregnancy in women previously diagnosed with Budd-Chiari syndrome and/or portal vein thrombosis, with and without concomitan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d134f28f322d5fde0c07bed41c087d6
https://doi.org/10.1111/1471-0528.16915

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

Autor: Eva N. Hamulyák, Saskia Middeldorp, Joost G. Daams, Bart J. Biemond, Frank W.G. Leebeek, Peter A. W. te Boekhorst, Mandy N. Lauw

Publikováno v: Blood Advances, 5, 113-121
Blood Advances, 5, 1, pp. 113-121
Blood Adv

Contains fulltext : 232734.pdf (Publisher’s version ) (Open Access) Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of recurrent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5e730cdbe6e594f65a5fc2f49a97b0
https://doi.org/10.1182/bloodadvances.2020003628

Emergencies on direct oral anticoagulants

Autor: Herm Jan M. Brinkman, Saskia Middeldorp, Barbara A. Hutten, Marjolein P. A. Brekelmans, Michiel Coppens, Marieke J. H. A. Kruip, Eva N. Hamulyák, Rahat A. Abdoellakhan, Karina Meijer, Peter E. Westerweel, Hugo ten Cate, Renske H. Olie, Marleen Zuurveld, Roisin Bavalia

Publikováno v: Research and practice in thrombosis and haemostasis, 4(4), 569-581. Wiley
Research and Practice in Thrombosis and Haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 569-581 (2020)
Research and practice in thrombosis and haemostasis, 4(4), 569-581. Wiley-Blackwell Publishing Ltd

Background In the initial absence of specific reversal agents for factor Xa inhibitors (FXa-Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f0368b4df92c7256a467c04bad2999
https://hdl.handle.net/11370/90876bf2-f7b8-4774-a8b9-77266e16545a

Heavy menstrual bleeding on direct factor Xa inhibitors

Autor: Anne Timmermans, Luuk J. J. Scheres, Saskia Middeldorp, Maria E. de Lange, Pieter Willem Kamphuisen, Hanke M. G. Wiegers, Eva N. Hamulyák, Barbara A. Hutten, M.R. Nijziel, Marije ten Wolde, Laura M. Faber, Laurens Nieuwenhuizen, Frederikus A. Klok, Sanne van Wissen, Marieke J. H. A. Kruip, Harry R. Büller, Paula F. Ypma, Peter E. Westerweel, Marcel M. C. Hovens

Publikováno v: Research and Practice in Thrombosis and Haemostasis, 5, 1, pp. 223-230
Research and Practice in Thrombosis and Haemostasis, 5(1), 223-230. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 223-230 (2021)
Research and Practice in Thrombosis and Haemostasis, 5, 223-230
Research and practice in thrombosis and haemostasis, 5(1), 223-230. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, 5(1), 223-230. WILEY

Contains fulltext : 235296.pdf (Publisher’s version ) (Open Access) BACKGROUND: In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa046677f417afaae1a604eb04b729d
https://hdl.handle.net/1887/3184895